金吾财讯 | 诺和诺德(NVO)盘前跌超15%，截至发稿，报40.09美元。消息面上，诺和诺德下一代减肥药物CagriSema在一项试验中达到的减重效果不如同业美国礼来公司的畅销药物。诺和诺德今日发表声明指，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。相比之下，礼来的tirzepatide减重效果为23.6%。
金吾财讯 | 诺和诺德(NVO)盘前跌超15%，截至发稿，报40.09美元。消息面上，诺和诺德下一代减肥药物CagriSema在一项试验中达到的减重效果不如同业美国礼来公司的畅销药物。诺和诺德今日发表声明指，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。相比之下，礼来的tirzepatide减重效果为23.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.